Cargando…
Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: study protocol for a randomized controlled superiority trial
BACKGROUND: There are no specific generally accepted therapies for the coronavirus disease 2019 (COVID-19). The full spectrum of COVID-19 ranges from asymptomatic disease to mild respiratory tract illness to severe pneumonia, acute respiratory distress syndrome (ARDS), multisystem organ failure, and...
Autores principales: | Villar, Jesús, Añón, José M., Ferrando, Carlos, Aguilar, Gerardo, Muñoz, Tomás, Ferreres, José, Ambrós, Alfonso, Aldecoa, César, Suárez-Sipmann, Fernando, Thorpe, Kevin E., Jüni, Peter, Slutsky, Arthur S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429135/ https://www.ncbi.nlm.nih.gov/pubmed/32799933 http://dx.doi.org/10.1186/s13063-020-04643-1 |
Ejemplares similares
-
Evaluating the efficacy of dexamethasone in the treatment of patients with persistent acute respiratory distress syndrome: study protocol for a randomized controlled trial
por: Villar, Jesús, et al.
Publicado: (2016) -
Unsuccessful and Successful Clinical Trials in Acute Respiratory Distress Syndrome: Addressing Physiology-Based Gaps
por: Villar, Jesús, et al.
Publicado: (2021) -
Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS
por: Ferrando, Carlos, et al.
Publicado: (2020) -
Correction to: Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS
por: Ferrando, Carlos, et al.
Publicado: (2020) -
Monitoring Expired CO(2) Kinetics to Individualize Lung-Protective Ventilation in Patients With the Acute Respiratory Distress Syndrome
por: Suárez-Sipmann, Fernando, et al.
Publicado: (2021)